Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes
Top Cited Papers
Open Access
- 4 October 2016
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 316 (13), 1383-1391
- https://doi.org/10.1001/jama.2016.14568
Abstract
Treatment with statins, the pharmacological agents of choice for low-density lipoprotein cholesterol (LDL-C)–lowering therapy in cardiovascular prevention,1,2 is associated with weight gain and a higher incidence of new-onset type 2 diabetes.3-5 Ezetimibe, an inhibitor of the LDL-C transporter Niemann-Pick C1-Like 1 (NPC1L1),6,7 has been approved as a lipid-lowering agent, but it is unclear whether its use will be associated with an adverse metabolic risk profile.Keywords
This publication has 42 references indexed in Scilit:
- Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathwaysNature Genetics, 2012
- Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetesNature Genetics, 2012
- A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistanceNature Genetics, 2012
- Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traitsNature Genetics, 2012
- GCTA: A Tool for Genome-wide Complex Trait AnalysisAmerican Journal of Human Genetics, 2010
- METAL: fast and efficient meta-analysis of genomewide association scansBioinformatics, 2010
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsThe Lancet, 2010
- Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challengeNature Genetics, 2010
- SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMapBioinformatics, 2008
- Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotypeProceedings of the National Academy of Sciences of the United States of America, 2004